Cargando…

Eyelid skin trichilemmoma and underlying local malignancy: is an aggressive treatment necessary?

OBJECTIVE: Trichilemmoma is a benign tumour derived from the outer root sheath of hair follicles. Trichilemmoma can be associated with basal cell carcinoma (BCC), either as a collision lesion or from malignant transformation. This study evaluates malignancy associated with eyelid trichilemmoma and p...

Descripción completa

Detalles Bibliográficos
Autores principales: Putri, Christine Anggun, Mudhar, Hardeep Singh, Meeney, Adam, Tan, Jennifer H Y
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7319780/
https://www.ncbi.nlm.nih.gov/pubmed/32617416
http://dx.doi.org/10.1136/bmjophth-2020-000513
_version_ 1783551114806820864
author Putri, Christine Anggun
Mudhar, Hardeep Singh
Meeney, Adam
Tan, Jennifer H Y
author_facet Putri, Christine Anggun
Mudhar, Hardeep Singh
Meeney, Adam
Tan, Jennifer H Y
author_sort Putri, Christine Anggun
collection PubMed
description OBJECTIVE: Trichilemmoma is a benign tumour derived from the outer root sheath of hair follicles. Trichilemmoma can be associated with basal cell carcinoma (BCC), either as a collision lesion or from malignant transformation. This study evaluates malignancy associated with eyelid trichilemmoma and principles of treatment. METHODS AND ANALYSIS: Retrospective study involving biopsy-proven eyelid trichilemmoma cases over 14 years encountered at a tertiary referral centre. Presenting features, differential diagnosis, type and number of operations required and histopathological features including coexisting BCC were analysed. RESULTS: We identified 36 cases with an average age of 66 years. The clinical differential diagnoses were mainly BCC (44%), papilloma (36%) and squamous cell carcinoma (SCC) (3%). Three patients (8%) had trichilemmoma with associated BCC. Of the 19 cases (53%) of trichilemmomas without BCC with equivocal surgical margins, seven patients (19%) opted for further excision while 12 patients (33%) opted for observation and were discharged. A patient re-presented two years later with invasive BCC. Overall, 11% of our biopsy-proven eyelid trichilemmoma cases were associated with BCC. CONCLUSION: Patients should be informed that a proportion of incompletely excised eyelid trichilemmomas may conceal underlying BCC. Therefore, further surgery to achieve clear surgical margins should be offered. Patients who opt for observation should be offered 6-monthly follow-up for three to five years. Alternatively, they can be discharged with advice to report any recurrence of lumps, skin changes or loss of lashes at the site of previous lesion.
format Online
Article
Text
id pubmed-7319780
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-73197802020-07-01 Eyelid skin trichilemmoma and underlying local malignancy: is an aggressive treatment necessary? Putri, Christine Anggun Mudhar, Hardeep Singh Meeney, Adam Tan, Jennifer H Y BMJ Open Ophthalmol Original Research OBJECTIVE: Trichilemmoma is a benign tumour derived from the outer root sheath of hair follicles. Trichilemmoma can be associated with basal cell carcinoma (BCC), either as a collision lesion or from malignant transformation. This study evaluates malignancy associated with eyelid trichilemmoma and principles of treatment. METHODS AND ANALYSIS: Retrospective study involving biopsy-proven eyelid trichilemmoma cases over 14 years encountered at a tertiary referral centre. Presenting features, differential diagnosis, type and number of operations required and histopathological features including coexisting BCC were analysed. RESULTS: We identified 36 cases with an average age of 66 years. The clinical differential diagnoses were mainly BCC (44%), papilloma (36%) and squamous cell carcinoma (SCC) (3%). Three patients (8%) had trichilemmoma with associated BCC. Of the 19 cases (53%) of trichilemmomas without BCC with equivocal surgical margins, seven patients (19%) opted for further excision while 12 patients (33%) opted for observation and were discharged. A patient re-presented two years later with invasive BCC. Overall, 11% of our biopsy-proven eyelid trichilemmoma cases were associated with BCC. CONCLUSION: Patients should be informed that a proportion of incompletely excised eyelid trichilemmomas may conceal underlying BCC. Therefore, further surgery to achieve clear surgical margins should be offered. Patients who opt for observation should be offered 6-monthly follow-up for three to five years. Alternatively, they can be discharged with advice to report any recurrence of lumps, skin changes or loss of lashes at the site of previous lesion. BMJ Publishing Group 2020-06-25 /pmc/articles/PMC7319780/ /pubmed/32617416 http://dx.doi.org/10.1136/bmjophth-2020-000513 Text en © Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.
spellingShingle Original Research
Putri, Christine Anggun
Mudhar, Hardeep Singh
Meeney, Adam
Tan, Jennifer H Y
Eyelid skin trichilemmoma and underlying local malignancy: is an aggressive treatment necessary?
title Eyelid skin trichilemmoma and underlying local malignancy: is an aggressive treatment necessary?
title_full Eyelid skin trichilemmoma and underlying local malignancy: is an aggressive treatment necessary?
title_fullStr Eyelid skin trichilemmoma and underlying local malignancy: is an aggressive treatment necessary?
title_full_unstemmed Eyelid skin trichilemmoma and underlying local malignancy: is an aggressive treatment necessary?
title_short Eyelid skin trichilemmoma and underlying local malignancy: is an aggressive treatment necessary?
title_sort eyelid skin trichilemmoma and underlying local malignancy: is an aggressive treatment necessary?
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7319780/
https://www.ncbi.nlm.nih.gov/pubmed/32617416
http://dx.doi.org/10.1136/bmjophth-2020-000513
work_keys_str_mv AT putrichristineanggun eyelidskintrichilemmomaandunderlyinglocalmalignancyisanaggressivetreatmentnecessary
AT mudharhardeepsingh eyelidskintrichilemmomaandunderlyinglocalmalignancyisanaggressivetreatmentnecessary
AT meeneyadam eyelidskintrichilemmomaandunderlyinglocalmalignancyisanaggressivetreatmentnecessary
AT tanjenniferhy eyelidskintrichilemmomaandunderlyinglocalmalignancyisanaggressivetreatmentnecessary